E-mail us: service@prospectnews.com Or call: 212 374 2800
Bank Loans - CLOs - Convertibles - Distressed Debt - Emerging Markets
Green Finance - High Yield - Investment Grade - Liability Management
Preferreds - Private Placements - Structured Products
 
Add to balance / Manage account  User:  Log out
Prospect News home > News index > List of issuers Y > Headlines for YM BioSciences Inc. > News item
Published on 2/23/2012 in the Prospect News PIPE Daily.

YM BioSciences plans to price public offering of common stock

BofA Merrill Lynch assists; proceeds fund drug development activities

By Devika Patel

Knoxville, Tenn., Feb. 23 - YM BioSciences Inc. announced plans to price a public sale of stock in a prospectus supplement filed with the Securities and Exchange Commission.

BofA Merrill Lynch is the bookrunning manager.

Proceeds will be used for drug development activities, general corporate purposes and working capital.

Based in Mississauga, Ont., YM develops treatments for cancer.


© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.